Investment Thesis
InspireMD demonstrates early market traction with 28.1% YoY revenue growth in the medical device sector, but faces critical fundamental challenges: operating losses of -$14M on only $3.4M revenue, negative operating cash flow of -$12.3M annually, and insufficient cash runway (11.4M cash = <12 months at current burn rate). The company requires major capital raises or dramatic operational improvements to achieve viability.
Strengths
- Positive 28.1% YoY revenue growth indicates market validation and product demand
- Conservative balance sheet with low leverage (0.11x Debt/Equity) and strong liquidity ratios (5.15x current ratio)
- Medical device sector with structural potential for higher margins and pricing power at scale
Risks
- Severe cash burn: -$12.3M operating cash flow with only $11.4M cash on hand (less than 12 months runway at current rate)
- Extreme unprofitability: -411% operating margin and -403% net margin on minimal revenue base
- Weak 20.2% gross margin for medtech suggests fundamental cost structure or operational issues
- No insider trading activity in 90 days may signal lack of confidence in near-term turnaround
- Pre-profitable early-stage company with high execution risk and likely significant shareholder dilution from future capital raises
Key Metrics to Watch
- Monthly/quarterly operating cash burn rate and months of cash runway remaining
- Gross margin expansion trajectory and operating expense reduction initiatives
- Quarterly revenue growth sustainability and timeline to positive operating cash flow
Financial Metrics
Revenue
3.4M
Net Income
-13.7M
EPS (Diluted)
$-0.16
Free Cash Flow
-12.5M
Total Assets
56.5M
Cash
11.4M
Profitability Ratios
Gross Margin
20.2%
Operating Margin
-411.4%
Net Margin
-402.9%
ROE
-31.4%
ROA
-24.2%
FCF Margin
-368.8%
Balance Sheet & Liquidity
Current Ratio
5.15x
Quick Ratio
4.82x
Debt/Equity
0.11x
Debt/Assets
22.8%
Interest Coverage
-117.46x
Long-term Debt
5.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T07:59:05.621777 |
Data as of: 2026-03-31 |
Powered by Claude AI